Jagsonpal Pharmaceuticals Ltd

During the Q1 FY27 Earnings Conference Call held on July 30, 2026, management reported a positive start to the year with a 9% growth in sales, reflecting an 18.9% growth in Pharmarack data compared to the industry growth of 11.6%. Operating EBITDA grew by 21% and net profits increased by 22%. A significant milestone was the acquisition of a controlling stake in Aequitas Healthcare for Rs.25 crores, which is anticipated to enhance Jagsonpal's entry into the hospital segment. Management highlighted a Rs.40 crores share buyback, which was oversubscribed and positively impacted return on capital employed. The company emphasized its focus on organic growth, brand building, and productivity improvements. The management also noted a change in the Board of Directors, welcoming Mr. Anil Kumar Matai as an Independent Director. Overall, the management expressed confidence in the company's growth trajectory and strategic initiatives.

Management emphasized strong growth and strategic acquisitions.